文章核心观点 公司的Fortel Ulcer Test获阿联酋卫生与预防部批准销售，可助力检测幽门螺杆菌感染，预防严重胃肠道疾病，扩大公司在中东地区影响力 [1][5] 分组1：产品信息 - Fortel Ulcer Test是检测幽门螺杆菌抗体的诊断工具，10分钟出准确结果 [2] - 该测试能让医疗保健提供者快速检测幽门螺杆菌感染，在阿联酋实现快速、便捷检测 [5][8] 分组2：行业现状 - 幽门螺杆菌感染约35%的美国人口和45%的五个最大欧洲国家人口，阿联酋感染率超50%，15 - 20%感染者会出现并发症 [3] - 胃癌是全球癌症相关死亡第3大常见原因，约80%病例归因于幽门螺杆菌感染，世卫组织将其列为1类致癌物 [4] 分组3：公司动态 - 此次批准进一步扩大公司在中东地区的业务版图，公司正与阿联酋经销商和医疗保健提供者合作推广产品 [5] - 公司致力于提供经济实惠、创新的诊断工具，通过早期疾病检测改善患者预后 [6] - 公司是全球生物医学技术公司，专注于胃肠道和炎症性疾病，有多种诊断和治疗产品正在开发中 [7]

文章核心观点 - 埃克索仿生公司宣布与仿生假肢与矫形集团建立商业联盟，后者成为埃克索Indego Personal设备的非独家经销商，双方合作旨在改善脊髓损伤患者生活质量并推动矫形和假肢行业发展 [1][3] 合作信息 - 埃克索仿生公司宣布仿生假肢与矫形集团为埃克索Indego Personal设备的非独家经销商，这是埃克索仿生首次进入矫形和假肢领域 [1] 产品特点 - 埃克索Indego Personal是可穿戴下肢动力外骨骼，能让脊髓损伤患者独立站立和行走，是唯一有模块化快速连接设计的便携式外骨骼设备，便于用户自行穿脱，也是已知最轻的商用外骨骼，易于操作、运输和储存，还具备先进步态模式，可让患者行走速度更快 [2] 双方表态 - 埃克索仿生首席执行官表示与仿生假肢与矫形集团的合作符合公司使命，该集团对市场动态、报销情况和患者需求有深入了解，是埃克索Indego Personal在矫形和假肢行业的最佳首个经销商 [3] - 仿生假肢与矫形集团全国业务发展经理称支持患者实现目标的创新与关怀护理是公司成功基石，埃克索Indego Personal设备将对患者生活产生积极影响，有潜力改变矫形和假肢行业，双方合作将助力脊髓损伤患者实现行走梦想 [3] 公司介绍 - 埃克索仿生是外骨骼解决方案领先开发商，专注用先进机器人技术改善健康和生活质量，其技术涵盖帮助瘫痪者行走和提升全球工作场所人类能力，公司总部位于旧金山湾区，在纳斯达克资本市场上市 [4] - 仿生假肢与矫形集团成立于2007年，是独立临床实践集团，在12个州运营，获美国矫形、假肢和足病治疗认证委员会全面认证，拥有各专业认证/持牌从业者 [5]

Newly allowed patent extends Wearable Devices’ innovative gesture technology into the domain of voice control YOKNEAM ILLIT, ISRAEL, April 23, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI")-powered touchless sensing wearables, today announced that the United States Patent and Trademark Office has allowed its patent titled “Gesture and Voice-Controlled Interface Device.” Thi ...

MINNEAPOLIS, April 23, 2025 (GLOBE NEWSWIRE) -- OneMedNet, a leader in AI-powered Real-World Data, has announced a strategic partnership with Protege, the AI training data platform, to enable real-time access, multimodal patient data for AI developers and researchers. Through this collaboration, OneMedNet’s data will be made available via Protege, expanding access to high-quality datasets for building next-generation AI solutions in healthcare. This partnership unlocks the potential for more precise, adapti ...

NEW YORK and SOUTH BURLINGTON, Vt., April 23, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) and Bullrock Energy Ventures (“Bullrock”) today announced that Apollo-managed funds (the “Apollo Funds”) have committed to fund up to $220 million for a new joint venture partnership with Bullrock related to a portfolio of community solar assets located in New York and New England. $100 million of Apollo’s equity commitment will fund the development of Bullrock’s nearly 500 MW pipeline of renewable energy assets. Based ...

RIMOUSKI, Québec, April 23, 2025 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is thrilled to announce the launch of its 2025 exploration programs in Northern New Brunswick. After weeks of compiling data, delivering assessment reports, and submitting permit applications, Puma is eagerly anticipating its return to the field. The technical team will be mobilized the first week of May, once the access roads to the different working areas are dry and safe. Work i ...

The Annual General Meeting, led by Chairman of the Board Dan Frohm, decided to: adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet, discharge the members of the Board and the Chief Executive Officer from liability for the financial year 2024,according to the proposal in the notice, distribute a dividend of SEK 4.15 per share for 2024. The record date for the dividend is proposed to be 25 April 2025 and it is expected that the dividend wil ...

文章核心观点 - 晚期生物制药公司Rezolute宣布定价承销发行普通股和预融资认股权证，预计毛收入约9000万美元，介绍了交易参与方、用途等情况 [1] 公司情况 - Rezolute是专注改善高胰岛素血症导致低血糖患者预后的晚期罕见病公司，其抗体疗法ersodetug可治疗所有类型HI，在临床试验和实际应用中对先天性HI和肿瘤HI治疗有显著益处 [7] 发行情况 - 公司按纳斯达克规则以市价定价承销发行，共发行20786923股普通股，每股3.25美元，向特定投资者发行预融资认股权证，可购买多达6905385股普通股，每份预融资认股权证3.2490美元，预计毛收入约9000万美元，还授予承销商30天选择权，可按发行价额外购买多达4153846股普通股 [1] - 发行的普通股和预融资认股权证均由公司提供，预计4月24日左右完成发行，需满足惯例成交条件 [2] 交易参与方 - 交易有新老投资者参与，包括Federated Hermes Kaufmann Funds、Blackstone Multi - Asset Investing等 [3] - Guggenheim Securities担任独家簿记管理人，BTIG、H.C. Wainwright & Co.和Jones担任牵头管理人，Craig - Hallum和Maxim Group LLC担任联合管理人，WG Partners LLP担任财务顾问 [4] 资金用途 - 公司打算将发行所得净收入用于研发、一般公司费用和营运资金需求 [4] 注册文件 - 与本次发行证券相关的S - 3表格货架注册声明已提交给美国证券交易委员会并于2023年11月29日生效，发行将通过招股说明书补充文件和随附招股说明书进行，相关文件可在SEC网站获取，也可联系Guggenheim Securities获取 [5] 联系方式 - 公司联系人Christen Baglaneas，邮箱cbaglaneas@rezolutebio.com，电话508 - 272 - 6717；媒体联系人Sarah Lima，邮箱Sarah@GalvinPR.com，电话(774) 766 - 0200 [10]

文章核心观点 公司将以VivoSim Labs, Inc.名义推进3D生物打印和传统技术业务，4月24日起公司名称变更为VivoSim Labs, Inc.，普通股将以新代码“VIVS”在纳斯达克资本市场交易 [1] 公司名称及股票交易变更 - 公司名称变更为VivoSim Labs, Inc.于4月24日生效 [1] - 公司普通股4月24日开盘起以新代码“VIVS”在纳斯达克资本市场交易 [1] 股东相关事项 - 现有股东无需对名称和代码变更采取行动 [2] - 公司普通股继续在纳斯达克资本市场上市，CUSIP编号（68620A302）不变 [2] 联系方式 - 联系邮箱为IR@organovo.com [4]

Montrouge, 23 April 2025 ORDINARY AND EXTRAORDINARY GENERAL MEETING OF CRÉDIT AGRICOLE S.A. OF 14 May 2025 Publication of the Notice of Meeting – Opening of the vote – Procedures for making the preparatory documents available Crédit Agricole S.A. informs its shareholders that its Ordinary and Extraordinary General Meeting will be held on Wednesday, 14 May 2025 at 9.30 am in Paris (75005), France, at Maison de la Mutualité, 24 rue Saint-Victor. A Notice of Meeting, including in particular the agenda and the ...